Annexon, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-22$6.96 RISE2026-03-30$4.96 PEAK2026-04-17$6.54 85d | -28.7% 67d | Missed | Missed | — | — | +31.9% 18d | Missed |
DROP2026-01-22$6.96 RISE2026-02-23$4.89 PEAK2026-04-17$6.54 85d | -29.7% 32d | Missed | Missed | — | — | +33.7% 53d | Missed |
DROP2026-01-22$6.96 RISE2026-02-13$4.89 PEAK2026-04-17$6.54 85d | -29.7% 22d | Missed | Missed | — | — | +33.7% 63d | Missed |
DROP2025-10-27$3.54 RISE2025-11-13$2.68 PEAK2026-01-22$6.96 87d | -24.3% 17d | Missed | Missed | — | — | +159.7% 70d | Missed |
DROP2025-07-03$2.89 RISE2025-09-03$2.05 PEAK2025-11-24$4.51 144d | -29.1% 62d | Missed | Missed | — | — | +120.0% 82d | Missed |
DROP2025-07-03$2.89 RISE2025-07-18$2.32 PEAK2025-09-26$3.37 85d | -19.7% 15d | Missed | Missed | — | — | +45.3% 70d | Missed |
DROP2025-01-02$5.50 RISE2025-04-10$1.38 PEAK2025-07-03$2.89 182d | -74.9% 98d | Missed | Missed | — | — | +109.4% 84d | Missed |
DROP2024-03-27$7.81 RISE2024-07-05$4.49 PEAK2024-09-13$7.20 170d | -42.5% 100d | Missed | Missed | — | — | +60.4% 70d | Missed |
DROP2024-03-27$7.81 RISE2024-05-17$4.33 PEAK2024-06-05$6.79 70d | -44.6% 51d | Missed | Missed | — | — | +56.8% 19d | Missed |
DROP2024-03-01$5.97 RISE2024-03-11$4.50 PEAK2024-03-27$7.81 26d | -24.6% 10d | Missed | Missed | — | — | +73.6% 16d | Missed |
DROP2024-01-02$4.84 RISE2024-02-02$4.03 PEAK2024-03-27$7.81 85d | -16.7% 31d | Missed | Missed | — | — | +93.8% 54d | Missed |
DROP2023-07-12$3.84 RISE2023-10-13$1.63 PEAK2024-01-02$4.84 174d | -57.6% 93d | Missed | Missed | — | — | +196.9% 81d | Missed |
DROP2023-01-27$7.46 RISE2023-05-25$2.10 PEAK2023-07-12$3.84 166d | -71.8% 118d | Missed | Missed | — | — | +82.9% 48d | Missed |
DROP2023-01-27$7.46 RISE2023-03-23$3.74 PEAK2023-05-17$6.37 110d | -49.9% 55d | Missed | Missed | — | — | +70.3% 55d | Missed |
DROP2022-09-20$6.63 RISE2023-01-05$4.54 PEAK2023-01-27$7.46 129d | -31.5% 107d | Missed | Missed | — | — | +64.3% 22d | Missed |
1–15 / 22 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome. Love described A
Annexon, Inc. (ANNX) Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsDouglas Love - CEO, President &...
Presenter SpeechTazeen Ahmad Good afternoon or still good morning, I think. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at
Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral rating and announces Price Target of $7.
Over the last 7 days, the United States market has risen by 2.2% and is up 31% over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential for substantial revenue expansion.
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 37.84 percent increase over losses of $(0.37) per share from the same
BRISBANE, Calif., May 06, 2026 -- Annexon, Inc. , a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact...
Annexon Inc. (NASDAQ:ANNX) is one of the small cap stocks with the highest upside potential. On March 30, the company reported its 2025 year-end financial results, highlighting a period of significant clinical and regulatory progress for its neuroinflammatory disease platform. The company ended the year with a strong balance sheet featuring $238.3 million in cash […]
Annexon Biosciences (NASDAQ:ANNX) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s shares have skyrocketed by 289.29% over the past year and by 39.45% year-to-date. On April 16, Needham analyst Joseph Stringer assigned a Buy rating on Annexon Biosciences and set a price target of $11.00. In March, Annexon […]
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual Needham Healthcare Conference, describing 2026 as a “win year” after more than a decade of work developing therapies that target the classical complement pathw
The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Annexon ( NASDAQ:ANNX...
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave Life, Perimeter Solutions, Praxis Precision, and Century Aluminum.
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.32) by 11.11 percent. This is a 15.15 percent increase over losses of $(0.33) per share from the same
Here is how American Well Corporation (AMWL) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
2026-03-20. The following slide deck was published by Annexon, Inc.
Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for vonoprument (ANX007), an intravitreal therapy being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration. Company leaders and invited retinal expe
Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and CEO Douglas Love emphasizing upcoming clinical catalysts, ongoing regulatory work, and preparations f
Belite Bio (BLTE) stock outlook: tinlarebant clinical data, 2026 filings, key FDA/EU risks, and $165/share valuation. See if itâs still a buy.
Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a detailed analysis.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANNX | -5.74% | -1.81% | +7.97% | +165.69% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -8.71% | +3.90% | +11.41% | +153.00% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 10.64M | $58.92M | 0.00% | Added+4.0% | 2026-03-31 |
| StateStreet | passive | 6.92M | $38.33M | 0.00% | Added+48.7% | 2026-03-31 |
| Citadel | multi-strat | 1.87M | $10.37M | 0.01% | Added+404.3% | 2026-03-31 |
| DEShaw | quant | 702.8K | $3.89M | 0.00% | Trimmed-32.8% | 2026-03-31 |
| RenTech | quant | 544.3K | $3.02M | 0.00% | Trimmed-32.2% | 2026-03-31 |
| Wellington | fundamental | 521.4K | $2.89M | 0.00% | Added+31.0% | 2026-03-31 |
| TwoSigma | quant | 471.4K | $2.61M | 0.00% | Added+42.0% | 2026-03-31 |
| TRowePrice | fundamental | 428.7K | $2.38K | 0.00% | Trimmed-3.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.24 | — | — |
| 2026-05-07 | -0.30 | -0.23 | +24.01% |
| 2026-03-30 | -0.32 | -0.28 | +11.20% |
| 2025-11-10 | -0.34 | -0.37 | -7.94% |
| 2025-08-14 | -0.36 | -0.34 | +5.96% |
| 2025-05-12 | -0.29 | -0.37 | -28.78% |
| 2025-03-03 | -0.29 | -0.33 | -12.53% |
| 2024-11-14 | -0.27 | -0.25 | +7.36% |
| 2024-08-12 | -0.24 | -0.23 | +2.86% |
| 2024-05-13 | -0.35 | -0.21 | +39.29% |
| 2024-03-26 | -0.48 | -0.36 | +24.71% |
| 2023-11-13 | -0.51 | -0.43 | +15.55% |
| 2023-08-07 | -0.54 | -0.47 | +12.52% |
| 2023-05-08 | -0.51 | -0.52 | -0.97% |
| 2023-03-06 | -0.53 | -0.48 | +9.43% |
| 2022-11-03 | -0.92 | -0.51 | +44.48% |